2 results match your criteria: "University Hospital Heidelberg and Mannheim[Affiliation]"
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation.
Ther Drug Monit
April 2016
*Pharmacology and Toxicology Laboratory, Biomedical Diagnostic Center (CDB), Hospital Clinic of Barcelona, University of Barcelona, Spain; †Klinikum Stuttgart, ZentralInstitut für Klinische Chemie und Laboratoriumsmedizin, Stuttgart, Germany; ‡Departments of Internal Medicine and Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, the Netherlands; §Department of Nephrology, University of Heidelberg, University Hospital Heidelberg and Mannheim, Heidelberg; ¶Medizinische Klinik mit Schwerpunkt Nephrologie, Charité Universitätsmedizin Berlin, Germany; ‖Louvain Centre for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique and Clinical Chemistry Department, Université catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; **C42 Clinical Research & Development, Department of Anesthesiology, University of Colorado, Aurora; ††Immunology Laboratory, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain; ‡‡Department of Cardiovascular Surgery, University Heart Center Hamburg, Germany; §§Department of Pharmacology, Oslo University Hospital, Norway; ¶¶U850 INSERM, Université de Limoges, CHU Limoges, France; ‖‖Division of Nephrology and Renal Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands; ***Liver Diseases Department, National Center for Liver Transplantation, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay; †††Department of Drug Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Poland; and ‡‡‡Department of Clinical Pharmacology, University Medical Center Göttingen, Georg-August University, Göttingen, Germany.
With current treatment regimens, a relatively high proportion of transplant recipients experience underimmunosuppression or overimmunosuppression. Recently, several promising biomarkers have been identified for determining patient alloreactivity, which help in assessing the risk of rejection and personal response to the drug; others correlate with graft dysfunction and clinical outcome, offering a realistic opportunity for personalized immunosuppression. This consensus document aims to help tailor immunosuppression to the needs of the individual patient.
View Article and Find Full Text PDFHigh interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis.
Nephrol Dial Transplant
April 2015
Department of Nephrology, University of Heidelberg, University Hospital Heidelberg and Mannheim, Heidelberg, Germany.
Article Synopsis
- Mycophenolic acid (MPA) is an immunosuppressant used to treat antineutrophil cytoplasm antibody-associated systemic vasculitis (AASV) by inhibiting an enzyme (IMPDH) that affects lymphocyte proliferation.
- A study involving 30 patients on MPA therapy revealed high variability in IMPDH activity, with those who relapsed showing higher baseline and increasing levels of this enzyme compared to stable patients.
- The findings suggest that pharmacodynamic monitoring of MPA could help identify patients at risk for inadequate immunosuppression, improving treatment outcomes in AASV.